Cardio Care Live

Online Events

PCSK9 Inhibitors and CV Risk Reduction

  • CME
    1.0

    The Emerging Role of PCSK9 Inhibitors and CV Risk Reduction

    Speakers:Michael J. Blaha, MD, MPH, Director of Clinical Research, Ciccarone Center for the Prevention of Heart Disease; Assistant Professor of Medicine
    Michael Miller, MD, FACC, FAHA, Professor of Cardiovascular Medicine, Epidemiology & Public Health

    Duration: 60 minutes

    Presented on: April 11, 2017

  • CME
    1.0

    CVD and PCSK9 Inhibitors: Analyzing the Outcome Studies and Understanding Their Implications

    Speakers:James A. Underberg, MD, MS, FACPM, FACP, FASH, FNLA, FASPC, Lipidology & Cardiovascular Disease Prevention, Clinical Assistant Professor of Medicine
    Marc S. Sabatine, MD, MPH, Lewis Dexter, MD Distinguished Chair in Cardiovascular Medicine

    Duration: 60 minutes

    Presented on: May 23, 2017

Pulmonary Arterial Hypertension

  • CME
    1.0

    New Approaches to Pulmonary Arterial Hypertension Management

    Speakers:Victor F. Tapson, MD, FCCP, FRCP, Professor of Medicine, Pulmonary Critical Care Medicine

    Duration: 60 minutes

    Presented on: May 24, 2017

Cardiovascular Disease, Diabetes, and Diabetes Treatments

  • CME
    1.0

    Diabetes and Cardiovascular Disease: What are the Issues?

    Speakers:Donald E. Cutlip, MD, Section Chief, Interventional Cardiology
    Richard Beaser, MD, Senior Physician, Medical Director, Professional Education
    Vivian A. Fonseca, MD, FRCP, Professor of Medicine and Pharmacology; Chief, Section of Endocrinology

    Duration: 60 minutes

    Presented on: March 1, 2017

  • CME
    1.0

    Cardiovascular Disease and Diabetes Medications: Analyzing the Outcome Studies and Understanding their Implications

    Speakers:Donald E. Cutlip, MD, Section Chief, Interventional Cardiology
    Richard Beaser, MD, Senior Physician, Medical Director, Professional Education
    Robert E. Heinig, MD, Director, Vascular Disease Prevention Program
    Vivian A. Fonseca, MD, FRCP, Professor of Medicine and Pharmacology; Chief, Section of Endocrinology

    Duration: 60 minutes

    Presented on: March 1, 2017

  • CME
    1.0

    Cardiovascular Disease and Diabetes Medications: Applying Trial Outcomes to Clinical Practice

    Speakers:Richard Beaser, MD, Senior Physician, Medical Director, Professional Education
    Michael Rocco, MD, Medical Director of Stress Testing and Cardiac Rehabilitation
    Stephen A. Brunton, MD, FAAFP, Executive Vice President
    Om P. Ganda, MD, Medical Director of the Lipid Clinic, Chair of the Clinical Oversight Committee

    Duration: 60 minutes

    Presented on: March 29, 2017

Speakers

PCSK9 Inhibitors and CV Risk Reduction

  • Michael J. Blaha, MD, MPH

    Michael J. Blaha, MD, MPH

    Michael J. Blaha, MD, MPH

    Director of Clinical Research, Ciccarone Center for the Prevention of Heart Disease; Assistant Professor of Medicine

    Michael J. Blaha, MD, MPH, is director of clinical research for the Johns Hopkins Ciccarone Center for the Prevention of Heart Disease in Baltimore, Maryland, and assistant professor of medicine at the Johns Hopkins Bloomberg School of Public Health. A practicing preventive noninvasive cardiologist, his work includes improving cardiovascular risk prediction through novel methods of early detection of atherosclerosis, including the use of cardiac computed tomography Dr Blaha is an associate editor for the journal Atherosclerosis, has published over 250 original papers, and two books on the metabolic syndrome. He is a founding member of The FIT Project, a principal investigator of the Coronary Artery Calcium Consortium, and co-director of the mobile health mActive Program at Johns Hopkins.
  • Michael Miller, MD, FACC, FAHA

    Michael Miller, MD, FACC, FAHA

    Michael Miller, MD, FACC, FAHA

    Professor of Cardiovascular Medicine, Epidemiology & Public Health

    Michael Miller, MD, FACC, FAHA, is professor of medicine at the University of Maryland School of Medicine in Baltimore and director of the Center for Preventive Cardiology for the University of Maryland Medical System. Dr Miller’s main research interests are disorders of lipid and lipoprotein metabolism; molecular studies of HDL cholesterol, triglycerides, and the postprandial response to dietary fat; nontraditional coronary risk factors; and clinical trials to reduce atherosclerosis. He serves on the Leadership Council of the American Heart Association (AHA), is a member of the AHA Nutrition and Lifestyle Committee, is past president of the American Society of Preventive Cardiology, and has published more than 250 scientific papers in leading medical journals such as JACC and JAMA.
  • James A. Underberg, MD, MS, FACPM, FACP, FASH, FNLA, FASPC

    James A. Underberg, MD, MS, FACPM, FACP, FASH, FNLA, FASPC

    James A. Underberg, MD, MS, FACPM, FACP, FASH, FNLA, FASPC

    Lipidology & Cardiovascular Disease Prevention, Clinical Assistant Professor of Medicine

    James A. Underberg, MD, MS, FACPM, FACP, FASH, FNLA, FASPC, is a clinical assistant professor of medicine at NYU School of Medicine and the NYU Center for Prevention of Cardiovascular Disease, and director of the Bellevue Hospital Lipid Clinic. Dr Underberg holds joint appointments in the Divisions of General Internal Medicine and Endocrinology at NYU. His clinical interests focus on the management of patients with lipids and lipoprotein disorders, and cardiovascular disease prevention. He maintains an active clinical research program in these areas, and has authored numerous articles and book chapters in the field of clinical lipidology. He is a diplomate of the American Board of Clinical Lipidology, and president-elect, board member and fellow of the National Lipid Association.
  • Marc S. Sabatine, MD, MPH

    Marc S. Sabatine, MD, MPH

    Marc S. Sabatine, MD, MPH

    Lewis Dexter, MD Distinguished Chair in Cardiovascular Medicine

    Marc S. Sabatine, MD, MPH, is chairman of the Thrombolysis in Myocardial Infarction (TIMI) Study Group, the Lewis Dexter, MD, Distinguished Chair in Cardiovascular Medicine at Brigham and Women’s Hospital, and a professor of medicine at Harvard Medical School in Boston, Massachusetts. As chairman of the TIMI Study Group, Dr Sabatine leads an academic research organization whose mission is to advance the knowledge and care of patients suffering from cardiovascular disease and its risk factors. He has led several large-scale, international, randomized controlled trials of novel antithrombotic, lipid-lowering and other pharmacotherapies, has a long-standing interest in pharmacogenetics, and has made seminal observations on the ability to use genetics for personalized medicine.

Pulmonary Arterial Hypertension

  • Victor F. Tapson, MD, FCCP, FRCP

    Victor F. Tapson, MD, FCCP, FRCP

    Victor F. Tapson, MD, FCCP, FRCP

    Professor of Medicine, Pulmonary Critical Care Medicine

    Victor F. Tapson, MD, FCCP, FRCP, is professor of medicine, director of the Clinical Research for the Women’s Guild Lung Institute and the Venous Thromboembolism and Pulmonary Vascular Disease Research Program, and associate director of the Pulmonary and Critical Care Division at Cedars-Sinai Medical Center in Los Angeles, California. Dr Tapson has devoted his career to patient care, research, and teaching in pulmonary hypertension and pulmonary embolism. He’s served on the steering committees for the World PH Guidelines, started the first PAH journal, Advances in PH, and served as worldwide PI or co-PI for several venous thromboembolism registries. He is currently PI for the OPTALYSE PE, BiO2 IVCF and FLARE clot-extraction studies, and the TAFIa clinical trial in acute PE.

Cardiovascular Disease, Diabetes, and Diabetes Treatments

  • Donald E. Cutlip, MD

    Donald E. Cutlip, MD

    Donald E. Cutlip, MD

    Section Chief, Interventional Cardiology

    Donald E. Cutlip, MD, is section chief of interventional cardiology and director of the Cardiac Catheterization Laboratory at Beth Israel Deaconess Medical Center, professor of medicine at Harvard Medical School, and a senior investigator at the Baim Institute for Clinical Research in Boston, Massachusetts. His clinical activities focus on coronary and valvular interventions, with a special interest in cardiovascular disease in patients with diabetes. He is involved in the design and management of numerous clinical trials of coronary, valvular, and peripheral vascular interventions. Dr Cutlip founded the Academic Research Consortium, and was a member of the ACC/AHA Task Force’s writing committee for key data elements and definitions for cardiovascular endpoint events in clinical trials.
  • Richard Beaser, MD

    Richard Beaser, MD

    Richard Beaser, MD

    Senior Physician, Medical Director, Professional Education

    Richard S. Beaser, M.D., is a practicing physician in the Joslin Clinic and holds the position of Associate Clinical Professor of Medicine at Harvard Medical School. He has also been the Medical Executive Director of Professional Education at Joslin and was instrumental in developing that activity at Joslin, a department he founded in 1990. Dr. Beaser graduated in 1973 from Trinity College, Hartford, and received his medical degree from Boston University School of Medicine in 1977. He served as a resident in internal medicine at the University of Massachusetts Medical Center in Worcester from 1977-1980. He was a fellow in endocrinology at the Joslin Diabetes Center, Boston, MA 1980-81, and in Endocrinology at the Lahey Clinic Medical Center, Burlington, MA 1981-82. Dr. Beaser has been on the staff of the Joslin Diabetes Center since 1982. He has held numerous past positions at Joslin, including Section Chief of the Adult Diabetology Practice, Medical Director of the Diabetes Treatment Unit, Coordinator of the Patient Education Section, and Medical Director of Joslin TrialNet, a clinical trials network. He has been a clinical research investigator, including the landmark Diabetes Control and Complications Trial. Dr. Beaser has authored 4 books: Joslin Diabetes Manual, Outsmarting Diabetes, The Joslin Guide to Diabetes, and Joslin’s Diabetes Deskbook: A Guide for Primary Care Providers. Dr Beaser is a well-known national lecturer on clinical diabetes and its comorbidities. He is the author of numerous publications in peer review journals, review articles, and book chapters. In his role as Medical Executive Director of Professional Education at Joslin Diabetes Center, and currently as the Chair of the CME Committee, Dr. Beaser has a specific focus on development or oversight of educational content for the department, targeting physicians, other medical professionals, and patients. He leads departmental conceptualization and development of projects and activities.
  • Vivian A. Fonseca, MD, FRCP

    Vivian A. Fonseca, MD, FRCP

    Vivian A. Fonseca, MD, FRCP

    Professor of Medicine and Pharmacology; Chief, Section of Endocrinology

    Vivian A. Fonseca, MD, FRCP, is a professor of medicine and pharmacology, the Tullis-Tulane Alumni Chair in Diabetes, and chief, Section of Endocrinology, at Tulane University Health Sciences Center in New Orleans, Louisiana. His current research interests include the prevention and treatment of diabetic complications and risk factor reduction in cardiovascular disease. Dr Fonseca is a fellow of the American Association of Clinical Endocrinologists, the Royal College of Physicians (London) and the American College of Physicians, and is a member of the Endocrine Society, the American Diabetes Association, and the International Diabetes Federation. He serves on numerous national and international committees, and has published more than 200 papers, review articles and book chapters.
  • Robert E. Heinig, MD

    Robert E. Heinig, MD

    Robert E. Heinig, MD

    Director, Vascular Disease Prevention Program

    Robert E. Heinig, MD, is clinical professor of medicine at the University of Rochester Medical School and director of the Vascular Diabetes Prevention Program at Rochester General Hospital in Rochester, New York. His current research interests include genetic and disease-related hyperlipidemia, normocholesterolemic dyslipidemia in insulin-resistant patients predisposing to coronary heart disease, and multiple risk factor modification in diabetic and insulin resistant patients with coronary heart disease. He belongs to several professional societies, including the American Diabetes Association, Endocrine Society, the American Society of Nephrology, and the American Association of Clinical Endocrinologists. Dr Heinig earned his MD from the University of Oregon School of Medicine in Portland.
  • Michael Rocco, MD

    Michael Rocco, MD

    Michael Rocco, MD

    Medical Director of Stress Testing and Cardiac Rehabilitation

    Michael Rocco, MD, is medical director of Cardiac Rehabilitation and Stress Testing, section of preventive cardiology, and a staff physician in the Departments of Cardiovascular Medicine and Molecular and Functional Imaging in the Division of Radiology at Cleveland Clinic in Ohio. His clinical research focuses primarily on the prognostic significance of asymptomatic ischemia, the evaluation of therapeutic interventions and exercise in the treatment and prevention of coronary artery disease, and the effect of drug therapy on lowering lipid levels. Dr Rocco lectures regionally and nationally, has published articles and abstracts in leading medical journals, and has authored chapters in textbooks. He received his medical degree from Duke University Medical Center in Durham, North Carolina.
  • Stephen A. Brunton, MD, FAAFP

    Stephen A. Brunton, MD, FAAFP

    Stephen A. Brunton, MD, FAAFP

    Executive Vice President

    Stephen Brunton, MD, FAAFP, is the executive vice president for education for the Primary Care Education Consortium, works in a group practice in Los Angeles, California, and is an adjunct clinical professor in the Department of Pharmacy Practice at Roseman University of Health Sciences in Salt Lake City, Utah. A board-certified family physician with a certificate of added qualifications in geriatrics, he earned his MD at Monash University Medical School in Melbourne, Australia. He is the former president of the California Academy of Family Physicians and the Association of Family Medicine Residency Directors. Dr Brunton has published numerous articles, chapters, and monographs on family medicine and related clinical topics, and serves in editorial capacities for numerous journals.
  • Om P. Ganda, MD

    Om P. Ganda, MD

    Om P. Ganda, MD

    Medical Director of the Lipid Clinic, Chair of the Clinical Oversight Committee

    Om P. Ganda, MD, FACE, is a board-certified specialist in internal medicine, endocrinology and metabolism, and clinical nutrition. He is a senior physician at the Joslin Diabetes Center and an associate professor of medicine at Harvard Medical School in Boston, Massachusetts. A co-investigator in the Diabetes Control and Complications Trial (DCCT), he has been engaged in clinical diabetes research for more than 3 decades. He is co-investigator of Epidemiology of Diabetes Interventions and Complications (EDIC), an ongoing, long-term, follow-up study. In addition to his clinical research and teaching, he directs the Lipid Clinic at Joslin, where he treats complex patients with dyslipidemia. Dr Ganda received his MD from the SMS Medical College, University of Rajasthan, Jaipur, India.

All Speakers

  • Michael J. Blaha, MD, MPH

    Michael J. Blaha, MD, MPH

    Michael J. Blaha, MD, MPH

    Director of Clinical Research, Ciccarone Center for the Prevention of Heart Disease; Assistant Professor of Medicine

    Michael J. Blaha, MD, MPH, is director of clinical research for the Johns Hopkins Ciccarone Center for the Prevention of Heart Disease in Baltimore, Maryland, and assistant professor of medicine at the Johns Hopkins Bloomberg School of Public Health. A practicing preventive noninvasive cardiologist, his work includes improving cardiovascular risk prediction through novel methods of early detection of atherosclerosis, including the use of cardiac computed tomography Dr Blaha is an associate editor for the journal Atherosclerosis, has published over 250 original papers, and two books on the metabolic syndrome. He is a founding member of The FIT Project, a principal investigator of the Coronary Artery Calcium Consortium, and co-director of the mobile health mActive Program at Johns Hopkins.
  • Michael Miller, MD, FACC, FAHA

    Michael Miller, MD, FACC, FAHA

    Michael Miller, MD, FACC, FAHA

    Professor of Cardiovascular Medicine, Epidemiology & Public Health

    Michael Miller, MD, FACC, FAHA, is professor of medicine at the University of Maryland School of Medicine in Baltimore and director of the Center for Preventive Cardiology for the University of Maryland Medical System. Dr Miller’s main research interests are disorders of lipid and lipoprotein metabolism; molecular studies of HDL cholesterol, triglycerides, and the postprandial response to dietary fat; nontraditional coronary risk factors; and clinical trials to reduce atherosclerosis. He serves on the Leadership Council of the American Heart Association (AHA), is a member of the AHA Nutrition and Lifestyle Committee, is past president of the American Society of Preventive Cardiology, and has published more than 250 scientific papers in leading medical journals such as JACC and JAMA.
  • James A. Underberg, MD, MS, FACPM, FACP, FASH, FNLA, FASPC

    James A. Underberg, MD, MS, FACPM, FACP, FASH, FNLA, FASPC

    James A. Underberg, MD, MS, FACPM, FACP, FASH, FNLA, FASPC

    Lipidology & Cardiovascular Disease Prevention, Clinical Assistant Professor of Medicine

    James A. Underberg, MD, MS, FACPM, FACP, FASH, FNLA, FASPC, is a clinical assistant professor of medicine at NYU School of Medicine and the NYU Center for Prevention of Cardiovascular Disease, and director of the Bellevue Hospital Lipid Clinic. Dr Underberg holds joint appointments in the Divisions of General Internal Medicine and Endocrinology at NYU. His clinical interests focus on the management of patients with lipids and lipoprotein disorders, and cardiovascular disease prevention. He maintains an active clinical research program in these areas, and has authored numerous articles and book chapters in the field of clinical lipidology. He is a diplomate of the American Board of Clinical Lipidology, and president-elect, board member and fellow of the National Lipid Association.
  • Marc S. Sabatine, MD, MPH

    Marc S. Sabatine, MD, MPH

    Marc S. Sabatine, MD, MPH

    Lewis Dexter, MD Distinguished Chair in Cardiovascular Medicine

    Marc S. Sabatine, MD, MPH, is chairman of the Thrombolysis in Myocardial Infarction (TIMI) Study Group, the Lewis Dexter, MD, Distinguished Chair in Cardiovascular Medicine at Brigham and Women’s Hospital, and a professor of medicine at Harvard Medical School in Boston, Massachusetts. As chairman of the TIMI Study Group, Dr Sabatine leads an academic research organization whose mission is to advance the knowledge and care of patients suffering from cardiovascular disease and its risk factors. He has led several large-scale, international, randomized controlled trials of novel antithrombotic, lipid-lowering and other pharmacotherapies, has a long-standing interest in pharmacogenetics, and has made seminal observations on the ability to use genetics for personalized medicine.
  • Victor F. Tapson, MD, FCCP, FRCP

    Victor F. Tapson, MD, FCCP, FRCP

    Victor F. Tapson, MD, FCCP, FRCP

    Professor of Medicine, Pulmonary Critical Care Medicine

    Victor F. Tapson, MD, FCCP, FRCP, is professor of medicine, director of the Clinical Research for the Women’s Guild Lung Institute and the Venous Thromboembolism and Pulmonary Vascular Disease Research Program, and associate director of the Pulmonary and Critical Care Division at Cedars-Sinai Medical Center in Los Angeles, California. Dr Tapson has devoted his career to patient care, research, and teaching in pulmonary hypertension and pulmonary embolism. He’s served on the steering committees for the World PH Guidelines, started the first PAH journal, Advances in PH, and served as worldwide PI or co-PI for several venous thromboembolism registries. He is currently PI for the OPTALYSE PE, BiO2 IVCF and FLARE clot-extraction studies, and the TAFIa clinical trial in acute PE.
  • Donald E. Cutlip, MD

    Donald E. Cutlip, MD

    Donald E. Cutlip, MD

    Section Chief, Interventional Cardiology

    Donald E. Cutlip, MD, is section chief of interventional cardiology and director of the Cardiac Catheterization Laboratory at Beth Israel Deaconess Medical Center, professor of medicine at Harvard Medical School, and a senior investigator at the Baim Institute for Clinical Research in Boston, Massachusetts. His clinical activities focus on coronary and valvular interventions, with a special interest in cardiovascular disease in patients with diabetes. He is involved in the design and management of numerous clinical trials of coronary, valvular, and peripheral vascular interventions. Dr Cutlip founded the Academic Research Consortium, and was a member of the ACC/AHA Task Force’s writing committee for key data elements and definitions for cardiovascular endpoint events in clinical trials.
  • Richard Beaser, MD

    Richard Beaser, MD

    Richard Beaser, MD

    Senior Physician, Medical Director, Professional Education

    Richard S. Beaser, M.D., is a practicing physician in the Joslin Clinic and holds the position of Associate Clinical Professor of Medicine at Harvard Medical School. He has also been the Medical Executive Director of Professional Education at Joslin and was instrumental in developing that activity at Joslin, a department he founded in 1990. Dr. Beaser graduated in 1973 from Trinity College, Hartford, and received his medical degree from Boston University School of Medicine in 1977. He served as a resident in internal medicine at the University of Massachusetts Medical Center in Worcester from 1977-1980. He was a fellow in endocrinology at the Joslin Diabetes Center, Boston, MA 1980-81, and in Endocrinology at the Lahey Clinic Medical Center, Burlington, MA 1981-82. Dr. Beaser has been on the staff of the Joslin Diabetes Center since 1982. He has held numerous past positions at Joslin, including Section Chief of the Adult Diabetology Practice, Medical Director of the Diabetes Treatment Unit, Coordinator of the Patient Education Section, and Medical Director of Joslin TrialNet, a clinical trials network. He has been a clinical research investigator, including the landmark Diabetes Control and Complications Trial. Dr. Beaser has authored 4 books: Joslin Diabetes Manual, Outsmarting Diabetes, The Joslin Guide to Diabetes, and Joslin’s Diabetes Deskbook: A Guide for Primary Care Providers. Dr Beaser is a well-known national lecturer on clinical diabetes and its comorbidities. He is the author of numerous publications in peer review journals, review articles, and book chapters. In his role as Medical Executive Director of Professional Education at Joslin Diabetes Center, and currently as the Chair of the CME Committee, Dr. Beaser has a specific focus on development or oversight of educational content for the department, targeting physicians, other medical professionals, and patients. He leads departmental conceptualization and development of projects and activities.
  • Vivian A. Fonseca, MD, FRCP

    Vivian A. Fonseca, MD, FRCP

    Vivian A. Fonseca, MD, FRCP

    Professor of Medicine and Pharmacology; Chief, Section of Endocrinology

    Vivian A. Fonseca, MD, FRCP, is a professor of medicine and pharmacology, the Tullis-Tulane Alumni Chair in Diabetes, and chief, Section of Endocrinology, at Tulane University Health Sciences Center in New Orleans, Louisiana. His current research interests include the prevention and treatment of diabetic complications and risk factor reduction in cardiovascular disease. Dr Fonseca is a fellow of the American Association of Clinical Endocrinologists, the Royal College of Physicians (London) and the American College of Physicians, and is a member of the Endocrine Society, the American Diabetes Association, and the International Diabetes Federation. He serves on numerous national and international committees, and has published more than 200 papers, review articles and book chapters.
  • Robert E. Heinig, MD

    Robert E. Heinig, MD

    Robert E. Heinig, MD

    Director, Vascular Disease Prevention Program

    Robert E. Heinig, MD, is clinical professor of medicine at the University of Rochester Medical School and director of the Vascular Diabetes Prevention Program at Rochester General Hospital in Rochester, New York. His current research interests include genetic and disease-related hyperlipidemia, normocholesterolemic dyslipidemia in insulin-resistant patients predisposing to coronary heart disease, and multiple risk factor modification in diabetic and insulin resistant patients with coronary heart disease. He belongs to several professional societies, including the American Diabetes Association, Endocrine Society, the American Society of Nephrology, and the American Association of Clinical Endocrinologists. Dr Heinig earned his MD from the University of Oregon School of Medicine in Portland.
  • Michael Rocco, MD

    Michael Rocco, MD

    Michael Rocco, MD

    Medical Director of Stress Testing and Cardiac Rehabilitation

    Michael Rocco, MD, is medical director of Cardiac Rehabilitation and Stress Testing, section of preventive cardiology, and a staff physician in the Departments of Cardiovascular Medicine and Molecular and Functional Imaging in the Division of Radiology at Cleveland Clinic in Ohio. His clinical research focuses primarily on the prognostic significance of asymptomatic ischemia, the evaluation of therapeutic interventions and exercise in the treatment and prevention of coronary artery disease, and the effect of drug therapy on lowering lipid levels. Dr Rocco lectures regionally and nationally, has published articles and abstracts in leading medical journals, and has authored chapters in textbooks. He received his medical degree from Duke University Medical Center in Durham, North Carolina.
  • Stephen A. Brunton, MD, FAAFP

    Stephen A. Brunton, MD, FAAFP

    Stephen A. Brunton, MD, FAAFP

    Executive Vice President

    Stephen Brunton, MD, FAAFP, is the executive vice president for education for the Primary Care Education Consortium, works in a group practice in Los Angeles, California, and is an adjunct clinical professor in the Department of Pharmacy Practice at Roseman University of Health Sciences in Salt Lake City, Utah. A board-certified family physician with a certificate of added qualifications in geriatrics, he earned his MD at Monash University Medical School in Melbourne, Australia. He is the former president of the California Academy of Family Physicians and the Association of Family Medicine Residency Directors. Dr Brunton has published numerous articles, chapters, and monographs on family medicine and related clinical topics, and serves in editorial capacities for numerous journals.
  • Om P. Ganda, MD

    Om P. Ganda, MD

    Om P. Ganda, MD

    Medical Director of the Lipid Clinic, Chair of the Clinical Oversight Committee

    Om P. Ganda, MD, FACE, is a board-certified specialist in internal medicine, endocrinology and metabolism, and clinical nutrition. He is a senior physician at the Joslin Diabetes Center and an associate professor of medicine at Harvard Medical School in Boston, Massachusetts. A co-investigator in the Diabetes Control and Complications Trial (DCCT), he has been engaged in clinical diabetes research for more than 3 decades. He is co-investigator of Epidemiology of Diabetes Interventions and Complications (EDIC), an ongoing, long-term, follow-up study. In addition to his clinical research and teaching, he directs the Lipid Clinic at Joslin, where he treats complex patients with dyslipidemia. Dr Ganda received his MD from the SMS Medical College, University of Rajasthan, Jaipur, India.
 

Partners

Academic

  • logo-einstein

Associations

  • Postgraduate Institute for Medicine
  • National Lipid Association

Publishers